Flow Cytometry Analysis
Systematic immunophenotyping interpretation
All Pathways
PathologyDiagnostic
Flow Cytometry Immunophenotyping Interpretation
Flow Cytometry Immunophenotyping Interpretation: Flow Cytometry Analysis → Specimen Assessment → Population Identification → Blasts Present? → Blast Lin...
Pathway Overview
11 steps
Algorithm Steps
11 total
01Start 02Action Specimen Assessment
Evaluate sample quality
- Viability (>80% preferred)
- Cell yield adequate
- Proper gating on viable cells
- Exclude debris and doublets
03Decision Population Identification
Identify abnormal populations
- SSC vs FSC characteristics
- CD45 vs SSC gating
- Identify blasts (CD45 dim, low SSC)
- Mature lymphocyte populations
- Monocytes, granulocytes
04Decision Blasts Present?
CD45 dim, low SSC population
05Action Blast Lineage Assignment
Determine B, T, or myeloid
- B-lymphoblastic: CD19+, CD10+, TdT+, CD34+/-
- T-lymphoblastic: cyCD3+, TdT+, CD7+, CD1a+/-
- AML: CD13+, CD33+, CD117+, MPO+/-
- Mixed phenotype: meets criteria for >1 lineage
06Action Clinical/Morphologic Correlation
Integrate all findings
- Review morphology (smear/biopsy)
- Correlate with cytogenetics/FISH
- Consider molecular studies
- WHO classification criteria
- Clinical staging information
07Outcome Final Diagnosis
WHO classification with immunophenotype
08Decision Lymphocyte Abnormality?
Clonal or aberrant population
09Action B-Cell Neoplasm Panel
Characterize B-cell lymphoma/leukemia
- Kappa/lambda restriction (clonality)
- CLL: CD5+, CD23+, CD19+, dim sIg
- MCL: CD5+, CD23-, cyclinD1+
- HCL: CD103+, CD25+, CD11c+
- Follicular: CD10+, BCL6+
- Marginal zone: CD5-, CD10-, CD23-
- Path rejoins step 06Shared downstream outcome
10Action T-Cell Neoplasm Panel
Characterize T-cell neoplasm
- CD4:CD8 ratio abnormality
- Loss of pan-T markers (CD5, CD7)
- T-LGL: CD3+, CD8+, CD57+
- ATLL: CD4+, CD25+, HTLV1+
- AITL: CD4+, CD10+, PD1+
- Path rejoins step 06Shared downstream outcome
11Action Plasma Cell Assessment
Myeloma evaluation
- CD38 bright, CD138+
- Cytoplasmic Ig restriction
- Aberrant: CD56+, CD19-, CD45-
- Normal: CD19+, CD56-
- Path rejoins step 06Shared downstream outcome
Guideline Source
ICCS/ESCCA Guidelines for Flow Cytometry
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Panel design varies by laboratory
- Requires correlation with morphology
- Some markers lack sensitivity/specificity alone
- Technical factors affect results
- Minimal residual disease requires specialized protocols
Applicable Regions
USAUUKEU
AU: RCPA flow cytometry guidelines
UK: BCSH flow cytometry standards
US: ICCS and CAP guidelines
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Flow Cytometry Immunophenotyping Interpretation?
The Flow Cytometry Immunophenotyping Interpretation is a diagnostic clinical algorithm for Pathology. It provides a structured decision tree to guide clinical decision-making, based on ICCS/ESCCA Guidelines for Flow Cytometry.
What guideline is the Flow Cytometry Immunophenotyping Interpretation based on?
This algorithm is based on ICCS/ESCCA Guidelines for Flow Cytometry (DOI: 10.1002/cyto.b.21905).
What are the limitations of the Flow Cytometry Immunophenotyping Interpretation?
Known limitations include: Panel design varies by laboratory; Requires correlation with morphology; Some markers lack sensitivity/specificity alone; Technical factors affect results; Minimal residual disease requires specialized protocols. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Flow Cytometry Immunophenotyping Interpretation appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free